Martin King, MD, PhD
Dr. Martin King is a board-certified radiation oncologist with expertise in treating genitourinary cancers. He currently serves as the Director of the Genitourinary Disease Site as well as the Director of the Brachytherapy Clinical Operations Leadership Team. He is an Associate Professor at Harvard Medical School.
Dr. King is the principal investigator of the INTREPID (INTermediate Risk Erection PreservatIon Trial) randomized controlled trial. This trial explores whether darolutamide, a novel second-generation anti-androgen inhibitor, can be utilized in place of traditional androgen deprivation therapy for patients receiving definitive radiation therapy. He is also the principal investigator of the Barrigel randomized controlled trial, which led to FDA approval of a hyaluronic acid rectal spacer for prostate radiation therapy. Dr. King also has interest in novel artificial intelligence (AI) algorithms for prostate MRI. He has shown that AI-derived tumor volume was prognostic for both radiation therapy and radical prostatectomy. Furthermore, this biomarker performed better than National Comprehensive Cancer Network risk stratification for radiation therapy.
After earning a degree in Chemical Engineering from the University of Illinois, USA, Dr. King pursued a PhD in Medical Physics and an MD from the University of Chicago, IL, USA. He completed a residency in Radiation Oncology at Stanford, CA, USA, and further specialized in a brachytherapy fellowship at Memorial Sloan Kettering (MSK), NY, USA.
Disclosures:
- Employment: Brigham and Women's Physician's Organization:Physician:Employee
- Compensation: Bayer Healthcare: Research Grants, Research Funding, Research Salary Support, Grant Research Funding-End Date: Ongoing ;Teleflex: Grant Research Funding, Salary Support-End Date: To present
- Ownership: none
- Leadership: none